Modality
Peptide
MOA
ALKi
Target
BET
Pathway
Amyloid
TTR AmyloidosisBCC
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
~Apr 2022
→ ~Jul 2023
Phase 2
Oct 2023
→ Jul 2025
Phase 2Current
NCT05526439
90 pts·BCC
2023-10→2025-07·Recruiting
90 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-139mo agoPh3 Readout· BCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-07-13 · 9mo ago
BCC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05526439 | Phase 2/3 | BCC | Recruiting | 90 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |